| Peter Ellis, MD | |
|
420 34th St, Bakersfield, CA 93301-2237 | |
| (661) 326-0088 | |
| Not Available |
| Full Name | Peter Ellis |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 38 Years |
| Location | 420 34th St, Bakersfield, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861561540 | NPI | - | NPPES |
| 00G607020 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | G60702 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bakersfield Memorial Hospital | Bakersfield, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pinnacle Emergency Physicians Of Bakersfield, A Professional Corp | 7214086321 | 30 |
News Archive
Scientists at Queen's University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a £1.74 million US-Ireland Research and Development Partnership grant.
In a new study in Nature, Brandeis University Howard Hughes Medical Investigator Dr. Dorothee Kern and collaborators pull back the curtain on the secret lives of enzymes, the ubiquitous proteins that catalyze chemical reactions in the cell.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.
Women who experience vulvodynia are more likely than those without the pain syndrome to have fibromyalgia, interstitial cystitis, and irritable bowel syndrome, research suggests.
› Verified 9 days ago
| Entity Name | Pinnacle Emergency Physicians Of Bakersfield, A Professional Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619153251 PECOS PAC ID: 7214086321 Enrollment ID: O20090520000375 |
News Archive
Scientists at Queen's University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a £1.74 million US-Ireland Research and Development Partnership grant.
In a new study in Nature, Brandeis University Howard Hughes Medical Investigator Dr. Dorothee Kern and collaborators pull back the curtain on the secret lives of enzymes, the ubiquitous proteins that catalyze chemical reactions in the cell.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.
Women who experience vulvodynia are more likely than those without the pain syndrome to have fibromyalgia, interstitial cystitis, and irritable bowel syndrome, research suggests.
› Verified 9 days ago
| Entity Name | Grand Avenue Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962913632 PECOS PAC ID: 7315206653 Enrollment ID: O20180112002313 |
News Archive
Scientists at Queen's University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a £1.74 million US-Ireland Research and Development Partnership grant.
In a new study in Nature, Brandeis University Howard Hughes Medical Investigator Dr. Dorothee Kern and collaborators pull back the curtain on the secret lives of enzymes, the ubiquitous proteins that catalyze chemical reactions in the cell.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.
Women who experience vulvodynia are more likely than those without the pain syndrome to have fibromyalgia, interstitial cystitis, and irritable bowel syndrome, research suggests.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Ellis, MD 3838 San Dimas St, Suite B-100, Bakersfield, CA 93301-2284 Ph: (661) 326-0088 | Peter Ellis, MD 420 34th St, Bakersfield, CA 93301-2237 Ph: (661) 326-0088 |
News Archive
Scientists at Queen's University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a £1.74 million US-Ireland Research and Development Partnership grant.
In a new study in Nature, Brandeis University Howard Hughes Medical Investigator Dr. Dorothee Kern and collaborators pull back the curtain on the secret lives of enzymes, the ubiquitous proteins that catalyze chemical reactions in the cell.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.
Women who experience vulvodynia are more likely than those without the pain syndrome to have fibromyalgia, interstitial cystitis, and irritable bowel syndrome, research suggests.
› Verified 9 days ago
Dr. Shannon K. Grant, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 Old River Rd, Bakersfield, CA 93311 Phone: 661-663-6275 Fax: 661-326-8022 | |
Dr. Michael Darin Niedens, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1830 Flower St, Bakersfield, CA 93305 Phone: 661-326-2667 | |
Rick Daniel Ornum Figurasin, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2615 Chester Ave, Bakersfield, CA 93301 Phone: 661-869-6227 | |
Albert Ko, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 9900 Stockdale Hwy, Suite 105, Bakersfield, CA 93311 Phone: 661-410-9500 | |
Lev Libet, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Trailer #2 Dept Of Emergency Medicine, Bakersfield, CA 93306 Phone: 661-326-2168 | |
Dr. Adria Elene Ottoboni, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 Fax: 661-326-2165 | |
Dr. John Eric Fortenberry, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 Old River Rd, Bakersfield, CA 93311 Phone: 661-326-8021 Fax: 661-326-8022 |